Intracranial Hemorrhages

• 

  Subject Areas on Research

  • 30-day mortality and readmission after hemorrhagic stroke among Medicare beneficiaries in Joint Commission primary stroke center-certified and noncertified hospitals. 
  • A blood-based biomarker panel to detect acute stroke. 
  • A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease. 
  • Acute coronary syndromes. STREAMlining care for patients with STEMI. 
  • Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors. 
  • Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials. 
  • Advances in primary stroke prevention. 
  • Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. 
  • Antecedents and Outcomes of Abnormal Cranial Imaging in Moderately Preterm Infants. 
  • Apolipoprotein E epsilon 2 is associated with new hemorrhage risk in brain arteriovenous malformations. 
  • Approach to Imaging in Patients with Spontaneous Intracranial Hemorrhage. 
  • Association of common candidate variants with vascular malformations and intracranial hemorrhage in hereditary hemorrhagic telangiectasia. 
  • Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. 
  • Brain ablation in the rat cerebral cortex using a tunable-free electron laser. 
  • Brain microvascular injury and white matter disease provoked by diabetes-associated hyperamylinemia. 
  • Cerebellar hemorrhage from a delayed cervical spine hardware migration. 
  • Chronic kidney disease and stroke. 
  • Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. 
  • Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. 
  • Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke: Findings From Get With The Guidelines-Stroke. 
  • Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. 
  • Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus. 
  • Contemporary trends and predictors of postacute service use and routine discharge home after stroke. 
  • Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. 
  • Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty. 
  • Declining stroke mortality in young adults: hope and concern. 
  • Delays in Door-to-Needle Times and Their Impact on Treatment Time and Outcomes in Get With The Guidelines-Stroke. 
  • Disseminated aspergillosis involving the brain: distribution and imaging characteristics. 
  • Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. 
  • Early biomarkers of stroke. 
  • Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. 
  • Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). 
  • Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data. 
  • Efficacy of abciximab readministration in coronary intervention. 
  • Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. 
  • Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 2. 
  • Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. 
  • Finite element model predictions of intracranial hemorrhage from non-impact, rapid head rotations in the piglet. 
  • Genes and environment in neonatal intraventricular hemorrhage. 
  • Genetic considerations relevant to intracranial hemorrhage and brain arteriovenous malformations. 
  • Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. 
  • Hospitalized hemorrhagic stroke patients with renal insufficiency: clinical characteristics, care patterns, and outcomes. 
  • Hypertensive retinopathy and risk of stroke. 
  • Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. 
  • Impact of Institutional Volume on Outcomes of Catheter Directed Thrombolysis in the Treatment of Acute Proximal Deep Vein Thrombosis: A 6-Year US Experience (2005-2010). 
  • Incidence and occurrence of total (first-ever and recurrent) stroke. 
  • Influence of gestational age on death and neurodevelopmental outcome in premature infants with severe intracranial hemorrhage. 
  • Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. 
  • Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. 
  • Intraoperative rupture of brainstem cavernous malformation. Case report. 
  • Low LDL cholesterol, statins, and brain hemorrhage: should we worry? 
  • Management of incidental cavernous malformations: a review. 
  • Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. 
  • Monitoring and improving acute stroke care: The North Carolina Stroke Care Collaborative. 
  • New heparin dosing recommendations for patients with acute coronary syndromes. 
  • Polymorphisms in genes involved in inflammatory and angiogenic pathways and the risk of hemorrhagic presentation of brain arteriovenous malformations. 
  • Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy. 
  • Rapid growth of an infectious intracranial aneurysm with catastrophic intracranial hemorrhage. 
  • Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STrategic Reperfusion Early After Myocardial infarction trial. 
  • Refined bleeding estimates in adults starting anticoagulants. 
  • Reversal of warfarin associated coagulopathy with 4-factor prothrombin complex concentrate in traumatic brain injury and intracranial hemorrhage. 
  • Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial). 
  • Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. 
  • Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. 
  • Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial. 
  • Severe factor V deficiency presenting with intracranial haemorrhage during gestation. 
  • Sex differences in utilization and outcomes of catheter-directed thrombolysis in patients with proximal lower extremity deep venous thrombosis - Insights from the Nationwide Inpatient Sample. 
  • Spontaneous brain parenchymal hemorrhage: an approach to imaging for the emergency room radiologist. 
  • Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: a translational approach. 
  • Survey of patient and physician influences and decision-making regarding CT utilization for minor head injury. 
  • The complex relationship between cholesterol and brain hemorrhage. 
  • Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. 
  • Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. 
  • Toward solving the sedation-assessment conundrum: bi-spectral index monitoring and sedation interruption. 
  • Treatment of atrial fibrillation in East Asia: what is perception and what is reality? 
  • Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012. 
  • Unresolved issues in diagnosis and management of inherited bleeding disorders in the perinatal period: a White Paper of the Perinatal Task Force of the Medical and Scientific Advisory Council of the National Hemophilia Foundation, USA. 
  • Use and Outcomes of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients ≥90 Years of Age. 
  • Whats and whys with neonatal CT. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • James, Michael Lucas, Associate Professor of Anesthesiology, Anesthesiology, Neuroanesthesia
  • Warner, David Samuel, Distinguished Professor of Anesthesiology, in the School of Medicine, Neurobiology